Disclosed is the use of cabazitaxel which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, and optionally further in combination with human granulocyte colony stimulating factor (G-CSF), in the manufacture of a medicament for its use in treating prostate cancer in a patient, where the patients treated have been previously treated with a docetaxel-based regimen, and wherein the patients have a neutrophil count greater than 1,500 cells/mm³. Also disclosed is a product comprising i) cabazitaxel ii) prednisone or prednisolone and iii) human granulocyte stimulating factor (G-CSF) wherein the combination is for the treatment of prostate cancer with an increased risk for neutropenia complications.
